Novartis AG
NVS
$114.29
$2.962.66%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.23B | 13.15B | 12.82B | 12.51B | 11.83B |
| Total Other Revenue | 352.00M | 405.00M | 349.00M | 360.00M | 291.00M |
| Total Revenue | 13.59B | 13.56B | 13.17B | 12.87B | 12.12B |
| Cost of Revenue | 3.22B | 3.31B | 3.24B | 3.17B | 3.10B |
| Gross Profit | 10.36B | 10.24B | 9.93B | 9.70B | 9.02B |
| SG&A Expenses | 3.06B | 3.50B | 3.13B | 3.09B | 2.84B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 148.00M | 112.00M | 8.00M | -7.00M | 374.00M |
| Total Operating Expenses | 8.80B | 9.50B | 8.76B | 8.57B | 8.73B |
| Operating Income | 4.79B | 4.06B | 4.41B | 4.30B | 3.39B |
| Income Before Tax | 4.41B | 3.29B | 3.39B | 3.84B | 3.13B |
| Income Tax Expenses | 798.00M | 465.00M | 200.00M | 595.00M | 441.00M |
| Earnings from Continuing Operations | 3.61B | 2.82B | 3.19B | 3.25B | 2.69B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -3.00M | -2.00M | 4.00M | -- | -- |
| Net Income | 3.61B | 2.82B | 3.19B | 3.25B | 2.69B |
| EBIT | 4.79B | 4.06B | 4.41B | 4.30B | 3.39B |
| EBITDA | 5.87B | 4.16B | 5.50B | 5.36B | 4.48B |
| EPS Basic | 1.83 | 1.42 | 1.59 | 1.60 | 1.32 |
| Normalized Basic EPS | 1.45 | 1.27 | 1.31 | 1.26 | 0.96 |
| EPS Diluted | 1.82 | 1.41 | 1.57 | 1.59 | 1.31 |
| Normalized Diluted EPS | 1.44 | 1.26 | 1.30 | 1.26 | 0.96 |
| Average Basic Shares Outstanding | 1.97B | 1.99B | 2.01B | 2.03B | 2.04B |
| Average Diluted Shares Outstanding | 1.98B | 2.00B | 2.03B | 2.05B | 2.06B |
| Dividend Per Share | -- | 3.86 | -- | -- | -- |
| Payout Ratio | 147.89% | 0.00% | -- | 74.46% | 193.71% |